Table 4.
PD1/PD-L1 antibody-vaccine combination treatment in locally advanced or metastatic TNBC.
| NCT Number | Other IDs | Intervention | Trial status |
|---|---|---|---|
| NCT03362060 | 17-328 | pembrolizumab + PVX-410 | recruiting |
| NCT02432963 | 15002, NCI-2015-00653 | pembrolizumab + p53-specific vaccine | active |
| NCT03761914 | SLS17-201/MK3475-770 | pembrolizumab + WT1-specific vaccine | recruiting |
| NCT02826434 | 16-132 | durvalumab + PVX-410 | active |
| NCT03199040 | 201710109, 1R01CA240983-01 | durvalumab + neoantigen DNA vaccine | recruiting |
| NCT03606967 | NCI-2018-01581, 10146, UM1CA186704 | durvalumab + Nab-paclitaxel+ neoantigen vaccine | unknown |
| NCT03289962 | GO39733, 2017-001475-23 | atezolizumab + neoantigen vaccine | recruiting |
PVX-410, multi-peptide vaccine (XBP1 US184-192; XBP1 SP367-375; CD138260-268; and CS1239-247).